{"filing":{"accession_number":"0001193125-26-347524","cik":"0001001233","ticker":"SGMO","company_name":"SANGAMO THERAPEUTICS, INC","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"d125617d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526347524/d125617d8k.htm"},"events":[{"id":27400,"run_id":24968,"accession_number":"0001193125-26-347524","anchor_item_number":"8.01","event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"The filing discloses that Sangamo Therapeutics filed a voluntary Chapter 11 petition on June 23, 2026 (case number 26-10989 in the U.S. Bankruptcy Court for the District of Delaware) and announces the conclusion of a court-supervised Section 363 asset auction process. While the Item 8.01 disclosure focuses on the asset sale results ($163.55 million in cash plus up to $100 million in milestones), the foundational event is the Chapter 11 bankruptcy filing itself, which is a terminal signal materially threatening the registrant's continued existence as an independent operating company.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28924,"accession_number":"0001193125-26-347524","item_number":"8.01","item_title":null,"event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Sangamo Therapeutics filed a voluntary Chapter 11 petition on June 23, 2026 (case number 26-10989 in the U.S. Bankruptcy Court for the District of Delaware) and announces the conclusion of a court-supervised Section 363 asset auction process. While the Item 8.01 disclosure focuses on the asset sale results ($163.55 million in cash plus up to $100 million in milestones), the foundational event is the Chapter 11 bankruptcy filing itself, which is a terminal signal materially threatening the registrant's continued existence as an independent operating company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T10:07:40.025488+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28924,"accession_number":"0001193125-26-347524","item_number":"8.01","item_title":null,"event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Sangamo Therapeutics filed a voluntary Chapter 11 petition on June 23, 2026 (case number 26-10989 in the U.S. Bankruptcy Court for the District of Delaware) and announces the conclusion of a court-supervised Section 363 asset auction process. While the Item 8.01 disclosure focuses on the asset sale results ($163.55 million in cash plus up to $100 million in milestones), the foundational event is the Chapter 11 bankruptcy filing itself, which is a terminal signal materially threatening the registrant's continued existence as an independent operating company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T10:07:40.025488+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-08-12"}]}